Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan;40(1):97-105.
doi: 10.1002/humu.23673. Epub 2018 Nov 19.

Variable population prevalence estimates of germline TP53 variants: A gnomAD-based analysis

Kelvin C de Andrade  1   2 , Megan N Frone  1 , Talia Wegman-Ostrosky  1   3 , Payal P Khincha  1 , Jung Kim  1 , Amina Amadou  4 , Karina M Santiago  2 , Fernanda P Fortes  2 , Nathanaël Lemonnier  4 , Lisa Mirabello  1 , Douglas R Stewart  1 , Pierre Hainaut  4 , Luiz P Kowalski  5 , Sharon A Savage  1 , Maria I Achatz  1   6
Affiliations

Variable population prevalence estimates of germline TP53 variants: A gnomAD-based analysis

Kelvin C de Andrade et al. Hum Mutat. 2019 Jan.

Abstract

Reports of variable cancer penetrance in Li-Fraumeni syndrome (LFS) have raised questions regarding the prevalence of pathogenic germline TP53 variants. We previously reported higher-than-expected population prevalence estimates in sequencing databases composed of individuals unselected for cancer history. This study aimed to expand and further evaluate the prevalence of pathogenic and likely pathogenic germline TP53 variants in the gnomAD dataset (version r2.0.2, n = 138,632). Variants were selected and classified based on our previously published algorithm and compared with alternative estimates based on three different classification databases: ClinVar, HGMD, and the UMD_TP53 database. Conservative prevalence estimates of pathogenic and likely pathogenic TP53 variants were within the range of one carrier in 3,555-5,476 individuals. Less stringent classification increased the approximate prevalence to one carrier in every 400-865 individuals, mainly due to the inclusion of the controvertible p.N235S, p.V31I, and p.R290H variants. This study shows a higher-than-expected population prevalence of pathogenic and likely pathogenic germline TP53 variants even with the most conservative estimates. However, these estimates may not necessarily reflect the prevalence of the classical LFS phenotype, which is based upon family history of cancer. Comprehensive approaches are needed to better understand the interplay of germline TP53 variant classification, prevalence estimates, cancer penetrance, and LFS-associated phenotype.

Keywords: Li-Fraumeni syndrome; TP53; gnomAD; pathogenic variant; prevalence; variant classification.

PubMed Disclaimer

Comment in

References

    1. Achatz MI, & Zambetti GP (2016). The Inherited p53 Mutation in the Brazilian Population. Cold Spring Harb Perspect Med, 6(12), 301–310. - PMC - PubMed
    1. Amadou A, Waddington Achatz MI, & Hainaut P (2017). Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: temporal phases of Li-Fraumeni syndrome. Curr Opin Oncol, 30(1), 23–29. - PubMed
    1. Amendola LM, Jarvik GP, Leo MC, McLaughlin HM, Akkari Y, Amaral MD, … Rehm HL (2016). Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium. Am J Hum Genet, 98(6), 1067–1076. - PMC - PubMed
    1. Arcand SL, Maugard CM, Ghadirian P, Robidoux A, Perret C, Zhang P, … Tonin PN (2008). Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families. Breast Cancer Res Treat, 108(3), 399–408. - PubMed
    1. Bouaoun L, Sonkin D, Ardin M, Hollstein M, Byrnes G, Zavadil J, & Olivier M (2016). TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data. Hum Mutat, 37(9), 865–876. - PubMed

Publication types

Substances